Recurrent Childhood Soft Tissue Sarcoma Recruiting Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs